title: Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sjögren's syndrome.
abstract: B cell activating factor (BAFF), also called the B lymphocyte stimulator, has been known to show increased expression in primary Sjögren's syndrome (pSS) which could explain increased B cell activation characteristic of this disease. Belimumab, a fully human IgG1λ recombinant monoclonal antibody directed against B lymphocyte stimulator (Blys), has been reported to be efficacious in systemic lupus erythematosus (SLE) through its B cell-mediated action. Randomized controlled trials of belimumab in a selected target population of pSS patients are further warranted.
authors: Internal Medicine, Lincoln Medical And Mental Health Center, New York, NY, USA.
authors: Sabeeda
authors: S
authors: Kadavath
authors: Slavica
authors: S
authors: Bobic
authors: Petros
authors: P
authors: Efthimiou
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects*; D066255:EGF Family of Proteins / Q000097:blood*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012859:Sjogren's Syndrome / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D066255:EGF Family of Proteins; D007166:Immunosuppressive Agents; C511911:belimumab
references: Mod Rheumatol. 2014 Jul;24(4):626-32
references: 24252043
references: Clin Exp Rheumatol. 1993 Nov-Dec;11(6):623-7
references: 8299253